Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients

Background Widespread use of screening mammography has allowed breast cancer to be detected at earlier stages.

This allows for increased customization of treatment and less aggressive management.

De-escalation of therapy plays an important role in decreasing treatment burden and improving patient quality of life.

This report examines cryoablation as the next step in the surgical de-escalation of breast cancer.

Methods Women with a diagnosis of clinically node-negative, estrogen receptor-positive (ER +), progesterone receptor-positive (PR +), human epidermal growth factor receptor 2-negative (HER2 −) infiltrating ductal carcinomas 1.5 cm or smaller underwent ultrasound-guided cryoablation.

Either the Visica 2 treatment system (before 2020) or the ProSense treatment system (since 2020) was used to perform the cryoablation.

Patients received mammograms and ultrasounds at a 6 months follow-up visit, and magnetic resonance images at baseline, then at 1 year follow-up intervals.

Adjuvant therapy decisions and disease status were recorded.

Results This study enrolled 32 patients who underwent 33 cryoablation procedures (1 patient had bilateral cancer).

One patient had a sentinel node biopsy in addition to clinical staging of the axilla.

For all the patients, adjuvant endocrine therapy was recommended, and six patients (18.75%) received adjuvant radiation.

Of the 32 patients, 20 (60.6%) have been followed up for 2 years or longer, with no residual or recurrent disease at the site of ablation.

Conclusion Cryoablation of the primary tumor foregoing sentinel node biopsy offers an oncologically safe and feasible minimally invasive office-based procedure option in lieu of surgery for patients with early-stage, low-risk breast cancer.